ABBV-295
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie · Phase 2 · Recruiting · Enrollment 360
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| ABBV-295 Arm 1 | n/r | n/r | n/r | n/r |
| ABBV-295 Arm 2 | n/r | n/r | n/r | n/r |
| ABBV-295 Arm 3 | n/r | n/r | n/r | n/r |
| ABBV-295 Arm 4 | n/r | n/r | n/r | n/r |
| ABBV-295 Arm 5 | n/r | n/r | n/r | n/r |
| ABBV-295 Arm 6 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- ABBV-295 Arm 1: endpoint not reported
- ABBV-295 Arm 2: endpoint not reported
- ABBV-295 Arm 3: endpoint not reported
- ABBV-295 Arm 4: endpoint not reported
- ABBV-295 Arm 5: endpoint not reported
- ABBV-295 Arm 6: endpoint not reported
- Placebo: endpoint not reported